Saturday, 5 September 2026European Markets

ADC SIIC Stock Tumbles 23% As Market Underperforms

Loading stream...

(vianews) - investors responded negatively to adc siic (aldv.pa) performance on wednesday, sending its stock plummeting 23.98% to eur0.07 by 16:08 est despite cac 40's rise of 0.48% compared to eur8,144.43 during this session. while adc siic recently experienced an upward trend, its 52-week high of eur0.08 remains 14% above current trading levels.

about adc siic

alliance developpement capital siic (adc siic) is a publicly traded real estate investment company focused on owning and managing residential properties near paris, france. formerly known as ad capital sa, adc siic's head office can be found in saint-josse-ten-noode, belgium.

yearly analysis

technical analysis

equity analysis

negative roe ratios indicate that a company is failing to generate profits efficiently and use shareholder equity effectively, thus depriving shareholders of its returns and not effectively managing their resources. an investment decision maker might take this into consideration when making their decisions as it indicates potential financial difficulties or mismanagement of resources by management practices that need further investigation; they might compare current roes against historical averages or those of similar companies within the same industry for comparison purposes.

more news about adc siic (aldv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com